Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2024-03-06 Director's Dealing
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is identified by the 'RNS Number' header and contains specific details about a 'Transaction by Person Discharging Managerial Responsibilities' (PDMR), namely Pascal Soriot, CEO of AstraZeneca PLC. It details the vesting of shares under a bonus plan and explicitly states it is an 'Initial notification' made in accordance with the EU Market Abuse Regulation. This type of insider transaction disclosure, especially when filed via RNS (Regulatory News Service), directly corresponds to the definition of Director's Dealing (DIRS). Although it is an RNS announcement, the content is highly specific to insider trading disclosure, making DIRS a more precise classification than the general RNS fallback.
2024-03-06 English
Director/PDMR Shareholding
Remuneration Information Classification · 99% confidence The document is an official notification released via RNS (RNS Number: 8452F) on March 6, 2024. The content explicitly details 'Transactions by Persons Discharging Managerial Responsibilities (PDMRs)' concerning the granting of share awards under company plans (AZDBP and AZPSP) to executive directors (CEO and CFO). This type of filing, reporting personal share transactions by directors and executives, directly corresponds to the definition of 'Director's Dealing' (Code: DIRS). Although it mentions the EU Market Abuse Regulation and refers to the Annual Report for performance measures, the core purpose and content are insider trading/dealing disclosures.
2024-03-06 English
Regulatory Filings 2024
Regulatory Filings
2024-03-06 English
8-A12B
Regulatory Filings Classification · 95% confidence The document is a Form 8-A filed with the SEC, which is used for the registration of certain classes of securities pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934. It details the registration of notes (debt securities) by AstraZeneca Finance LLC and AstraZeneca PLC, including descriptions of the securities and references to prospectuses and indentures. This form is a regulatory filing related to securities registration and does not contain financial statements, earnings data, or management discussion. It is not an annual report, earnings release, or any other financial report type. It is also not an announcement of a report but the actual registration statement form. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2024-03-05 English
EMA VALIDATES DATO-DXD MAAS FOR NSQ NSCLC AND BC
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains a detailed announcement about the European Medicines Agency (EMA) validating marketing authorisation applications (MAAs) for a drug, datopotamab deruxtecan, for certain cancer treatments. The document includes clinical trial information, regulatory progress, and company background. It is not a full annual or interim financial report, nor is it a transcript, audit report, or other specific financial filing. The Form 6-K is a regulatory filing used by foreign companies to report material information to the SEC. Given the nature of the content and the form type, this document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories. The document length (13,842 characters) and detailed content confirm it is not a brief announcement or a report publication announcement. Therefore, the classification is RNS with high confidence.
2024-03-04 English
EMA validates Dato-DXd MAAs for NSQ NSCLC and BC
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 3665F' and is dated '04 March 2024'. The content describes a regulatory update regarding the validation of marketing authorisation applications (MAAs) by the European Medicines Agency (EMA) for a drug (datopotamab deruxtecan). This type of announcement, which disseminates material, time-sensitive information via an official news service (RNS, regulated by the FCA), fits the description of a general regulatory announcement that doesn't fit a more specific category like 10-K, ER, or DIV. Since it is a formal regulatory news service release, the most appropriate classification is Regulatory Filings (RNS). The document length is substantial (14,829 chars), so it is not a simple RPA.
2024-03-04 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.